Sonoma Pharmaceuticals, Inc. (SNOA)
Company Description
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally.
The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.
It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds.
In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation.
The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016.
Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
| Country | United States |
| IPO Date | Jan 25, 2007 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Ms. Amy M. Trombly |
Contact Details
Address:
5445 Conestoga Court, Suite 150 Boulder, Colorado 80301 United States | |
| Phone | 800-759-9305 |
| Website | sonomapharma.com |
Stock Details
| Ticker Symbol | SNOA |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001367083 |
| CUSIP Number | 83558L204 |
| ISIN Number | US83558L2043 |
| Employer ID | 68-0423298 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amy M. Trombly | Chief Executive Officer, President and Director |
| Bruce Thornton | Chief Operating Officer and Corporate Secretary |
| Jerome Dvonch | Executive Officer |
| Chad White | Interim Chief Financial Officer |
| Dr. Robert Northey | Executive Vice President of Research & Development |
| Victoria Covel | Assistant Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 24, 2023 | 424B5 | Filing |
| Feb 24, 2023 | 8-K | Current Report |
| Feb 14, 2023 | 10-Q | Quarterly Report |
| Jan 31, 2023 | 8-K | Current Report |
| Jan 6, 2023 | 8-K | Current Report |
| Dec 30, 2022 | 8-K | Current Report |
| Dec 23, 2022 | 8-K | Current Report |
| Dec 23, 2022 | 424B3 | Prospectus |
| Nov 14, 2022 | 10-Q | Quarterly Report |
| Oct 7, 2022 | 8-K | Current Report |